CervoMed (CRVO) Stock Price, News & Analysis

Company Overview

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $2.24 to $2.43
• 50-Day Range: $1.90 to $14.08
• 52-Week Range: $1.80 to $26.38
• Volume: 276,492 shs
• Average Volume: 257,646 shs
• Market Capitalization: $14.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.00
• Consensus Rating: Hold

CervoMed Stock Analysis - MarketRank™

CervoMed scored higher than 60% of companies evaluated by MarketBeat, and ranked 455th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

CervoMed has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CervoMed has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CervoMed are expected to decrease in the coming year, from ($1.77) to ($1.82) per share.

Price to Book Value per Share Ratio

CervoMed has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

48.41% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in CervoMed has recently increased by 34.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CervoMed does not currently pay a dividend.

Dividend Growth

CervoMed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

48.41% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in CervoMed has recently increased by 34.90%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.87

News Sentiment

CervoMed has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CervoMed this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for CRVO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

4 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CervoMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.30% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 25.15% of the stock of CervoMed is held by institutions.

CRVO Stock Analysis - Frequently Asked Questions

How have CRVO shares performed this year?

CervoMed's stock was trading at $2.34 on January 1st, 2025. Since then, CRVO shares have decreased by 0.4% and is now trading at $2.33.
View the best growth stocks for 2025 here.

How were CervoMed's earnings last quarter?

CervoMed Inc. (NASDAQ:CRVO) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.14. The business earned $1.94 million during the quarter, compared to the consensus estimate of $1.75 million. CervoMed had a negative trailing twelve-month return on equity of 44.11% and a negative net margin of 118.68%.

How do I buy shares of CervoMed?

Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CervoMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRVO
• Previous Symbol: NASDAQ:CRVO
• CUSIP: N/A
• CIK: 1053691
• Web: diffusionpharma.com
• Phone: 14342200718
• Fax: 434-220-0722
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $42.00
• High Stock Price Target: $63.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +1,702.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,170,000.00
• Net Margins: -118.68%
• Pretax Margin: -118.68%
• Return on Equity: -44.11%
• Return on Assets: -39.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.04
• Quick Ratio: 15.04

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 2.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 6,170,000
• Free Float: 3,930,000
• Market Cap: $14.38 million
• Optionable: Not Optionable
• Beta: 1.62